The cost-effectiveness of screening for hereditary hemochromatosis in Germany: A remodeling study

Medical Decision Making

Volumn 29, Issue 2, 2009, Pages 224-238

  Rogowski, Wolf H ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Cost effectiveness analysis; Genetic predisposition to disease; Genetic screening; Germany; Hereditary hemochromatosis.

Indexed keywords

ADULT; ARTICLE; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; GENOTYPE; GERMANY; HEALTH CARE COST; HEMOCHROMATOSIS; HUMAN; MALE; PHENOTYPE; PROGENY; REIMBURSEMENT; SCREENING TEST;

ADULT; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GENETIC SCREENING; GENOTYPE; GERMANY; HEMOCHROMATOSIS; HUMANS; MALE; MODELS, ECONOMETRIC; PHENOTYPE; SENSITIVITY AND SPECIFICITY;

EID: 64549148979     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X08327112     Document Type: Article

References (58)

1. Human Genome Program. Genomics and Its Impact on Science and Society: A 2003 Primer. 2003 [cited 30 August 2005]. Available from: www.ornl.gov/hgmis/ publicat/primer/
2. Guttmacher AE, Collins FS Genomic medicine: a primer. N Engl J Med. 2002 ; 347: 1512-20. (Pubitemid 35257592)
3. Rogowski W. Current impact of gene technology on healthcare: a map of economic assessments. Health Pol. 2007 ; 80: 340-57.
4. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2006 ; 145: 209-23.
5. Adams PC, Barton JC Haemochromatosis. Lancet. 2007 ; 370: 1855-60. (Pubitemid 46126729)
6. Adams PC, Gregor JC, Kertesz AE, Valberg LS Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterology. 1995 ; 109: 177-88.
7. Adams PC, Kertesz AE, Valberg LS Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness. Hepatology. 1995 ; 22: 1720-7.
8. Adams PC, Valberg LS Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol. 1999 ; 94: 1593-600.
9. Asberg A., Tretli S., Hveem K., Bjerve KS Benefit of population-based screening for phenotypic hemochromatosis in young men. Scand J Gastroenterol. 2002 ; 37: 1212-9. (Pubitemid 35178688)
10. Buffone GJ, Beck JR Cost-effectiveness analysis for evaluation of screening programs: hereditary hemochromatosis. Clin Chem. 1994 ; 40: 1631-6.
11. El-Serag HB, Inadomi JM, Kowdley KV Screening for hereditary hemochromatosis in siblings and children of affected patients: a cost-effectiveness analysis. Ann Intern Med. 2000 ; 132: 261-9.
12. Gagné G., Reinharz D., Laflamme N., Adams P., Rousseau F. Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms. Clin Genet. 2007 ; 71: 46-58.
13. Schöffski O., Schmidtke J., Stuhrmann M. Cost-effectiveness of population-based genetic hemochromatosis screening. Community Genetics. 2000 ; 3: 2-11.
14. Stave GM, Mignogna JJ, Powell GS, Hunt CM Evaluation of a workplace hemochromatosis screening program. Am J Prev Med. 1999 ; 16: 303-6.
15. Rogowski W. Genetic screening by DNA technology: a systematic review of health economic evidence. Int J Technol Assess Health Care. 2006 ; 22: 327-37. (Pubitemid 44469439)
16. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG Replication validity of genetic association studies. Nat Genet. 2001 ; 29: 306-9.
17. Schmitt B., Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med. 2005 ; 143: 522-36. (Pubitemid 41377201)
18. Adams PC, Passmore L., Chakrabarti S., et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol. 2006 ; 4: 918-23 ; quiz 807.
19. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload- related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008 ; 358: 221-30.
20. Philips Z., Bojke L., Sculpher M., Claxton K., Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006 ; 24: 355-71.
21. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005 ; 352: 1769-78.
22. Krawczak M., Cooper DN, Schmidtke J. Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet. 2001 ; 69: 361-70. (Pubitemid 32695208)
23. Stuhrmann M., Hoy L., Nippert I., Schmidtke J. Genotype-based screening for hereditary hemochromatosis: II. Attitudes toward genetic testing and psychosocial impact-a report from a German pilot study. Genet Test. 2005 ; 9: 242-54. (Pubitemid 41507757)
24. Gabriel H., Stuhrmann M. Leitlinie zur molekulargenetischen Diagnostik der hereditären Hämochromatose. Medizinische Genetik. 2006 ; 18: 273-8. (Pubitemid 44681270)
25. Stuhrmann M., Strassburg C., Schmidtke J. Genotype-based screening for hereditary haemochromatosis: I. Technical performance, costs and clinical relevance of a German pilot study. Eur J Hum Genet. 2005 ; 13: 69-78. (Pubitemid 41507757)
26. Phatak PD, Guzman G., Woll JE, Robeson A., Phelps CE Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 1994 ; 154: 769-76. (Pubitemid 24115664)
27. Briggs A., Claxton K., Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford, UK: Oxford University Press; 2006.
28. Olynyk JK, Hagan SE, Cullen DJ, Beilby J., Whittall DE Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc. 2004 ; 79: 309-13. (Pubitemid 38269232)
29. Andersen RV, Tybjaerg-Hansen A., Appleyard M., Birgens H., Nordestgaard BG Hemochromatosis mutations in the general population: iron overload progression rate. Blood. 2004 ; 103: 2914-9.
30. Olynyk JK, Cullen DJ, Aquilia S., Rossi E., Summerville L., Powell LW A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999 ; 341: 718-24. (Pubitemid 29407371)
31. Burt MJ, George PM, Upton JD, et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut. 1998 ; 43: 830-6.
32. Delatycki MB, Allen KJ, Nisselle AE, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet. 2005 ; 366: 314-6.
33. Powell LW, Dixon JL, Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. 2006 ; 166: 294-301. (Pubitemid 43244317)
34. Adams PC, Reboussin DM, Press RD, et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med. 2007 ; 120: 999.e1-7.
35. Hicken BL, Tucker DC, Barton JC Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol. 2003 ; 98: 2072-7.
36. Siegel JE, Weinstein MC, Russell LB, Gold MR Recommendations for reporting cost-effectiveness analyses: Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 ; 276: 1339-41.
37. Krauth C., Hessel F., Klingelhofer HE, Schweikert B., Hansmeier T., Wasem J. Empirische Bewertungssätze in der gesundheitsöko nomischen Evaluation: Ein Vorschlag der AG Gesundheitsökonomische Methoden (AG MEG). Rehabilitation (Stuttg). 2005 ; 44: 297-306. (Pubitemid 41604934)
38. von der Schulenburg JMG, Greiner W., et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Gesundh Okon Qual Manage. 2007 ; 12: 285-90.
39. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002 ; 22: 417-30.
40. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. 2004 [cited 17 May 2005]. Available from: http://www.nice.org.uk/pdf/TAP-Methods.pdf
41. Haynes RB, McDonald HP, Garg AX Helping patients follow prescribed treatment: clinical applications. JAMA. 2002 ; 288: 2880-3.
42. McDonald HP, Garg AX, Haynes RB Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002 ; 288: 2868-79. (Pubitemid 35425073)
43. Haynes RB, McDonald H., Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002 ;(2). CD000011.
44. Niederau C., Fischer R., Purschel A., Stremmel W., Haussinger D., Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996 ; 110: 1107-9. (Pubitemid 26113751)
45. Milman N., Pedersen P., á Steig T., Byg KE, Graudal N., Fenger K. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol. 2001 ; 80: 737-44. (Pubitemid 34044096)
46. Grosse SD, Khoury MJ What is the clinical utility of genetic testing ? Genet Med. 2006 ; 8: 448-50.
47. Khoury MJ, McCabe LL, McCabe ER Population screening in the age of genomic medicine. N Engl J Med. 2003 ; 348: 50-8.
48. Power TE, Adams PC, Barton JC, et al. Psychosocial impact of genetic testing for hemochromatosis in the HEIRS Study: a comparison of participants recruited in Canada and in the United States. Genet Test. 2007 ; 11: 55-64. (Pubitemid 46557358)
49. Institute for Quality and Efficiency in Health Care. Methods for assessment of the relation of benefits to costs in the German statutory health care system. 2008 [cited 24 Jan 2008]. Available from: http://www.iqwig.de/ download/08-01-24-Methods-of-the-Relation-of-Benefits-to-Costs-Version-1-0.pdf
50. Adams PC, Speechley M., Kertesz AE Long-term survival analysis in hereditary hemochromatosis. Gastroenterology. 1991 ; 101: 368-72. (Pubitemid 26113751)
51. Palomaki GE, Haddow JE, Bradley LA, Richards CS, Stenzel TT, Grody WW Estimated analytic validity of HFE C282Y mutation testing in population screening: the potential value of confirmatory testing. Genet Med. 2003 ; 5: 440-3. (Pubitemid 37483413)
52. Bomford A., Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med. 1976 ; 45: 611-23.
53. Nisselle AE, Delatycki MB, Collins V., et al. Implementation of HaemScreen, a workplace-based genetic screening program for hemochromatosis. Clin Genet. 2004 ; 65: 358-67.
54. Barton JC, Acton RT, Dawkins FW, et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test. 2005 ; 9: 231-41. (Pubitemid 41507756)
55. Barton JC, Acton RT, Leiendecker-Foster C., et al. HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening. Genet Test. 2007 ; 11: 269-75. (Pubitemid 47614396)
56. Adams PC, Reboussin DM, Leiendecker-Foster C., et al. Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Clin Chem. 2005 ; 51: 1048-52. (Pubitemid 40740896)
57. Altenstetter C., Busse R. Health care reform in Germany: patchwork change within established governance structures. J Health Polit Policy Law. 2005 ; 30: 121-42. (Pubitemid 40627009)
58. McCune CA, Ravine D., Worwood M., Jackson HA, Evans HM, Hutton D. Screening for hereditary haemochromatosis within families and beyond. Lancet. 2003 ; 362: 1897-8. (Pubitemid 37518508)